grade
pharmaceutical primary standard
API family
nitrofurantoin
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1
InChI
1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
InChI key
NXFQHRVNIOXGAQ-YCRREMRBSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 呋喃妥因
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
M M Meyer et al.
The Journal of urology, 152(3), 938-940 (1994-09-01)
A 33-year-old woman received a cadaveric renal transplant for focal segmental glomerulosclerosis. Nitrofurantoin urinary prophylaxis was started on postoperative day 13 but coughing and mild hemoptysis began 2 days later. Diffuse infiltrates and worsening hemoptysis led to intubation and open
Edward Karpman et al.
The Journal of urology, 172(2), 448-453 (2004-07-13)
Many children with urological disease require long-term treatment with antibiotics. In many cases the choice of medical instead of surgical management hinges on the implied safety of certain drugs. Recently some groups have advocated subureteral injection procedures to avoid long-term
J Garau
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 14 Suppl 1, 198-202 (2007-12-25)
The progressive increase of extended-spectrum beta-lactamase (ESBL) -producing enteric bacteria in recent years has called for a re-evaluation of current antibiotic therapy for these infections. The activity and potential use of two old antimicrobials, nitrofurantoin and fosfomycin, and the new
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1464001-500MG | 04061838736802 |